SCG-002

N/A

Report date: 2023/01/08 14:03:51

Base Information

Drug NameSCG-002

Drug Alias NameSCG002

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity

TargetsNot applicable

Therapy Area/IndicationsLiver Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySingapore

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesGerman Cancer Research Center (Dkfz)Helmholtz Zentrum Munchen

China Registration ClassN/A

Develop Information

Active CompaniesGerman Cancer Research Center (Dkfz)Technical University Munich Helmholtz Zentrum Munchen

Inactive CompaniesN/A

Active IndicationsLiver Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A